Trasylol article ver. 2 – Trasylollawsuitcenter.com

In 2006 the serious problems with Trasylol kidney failure were brought to light in the first of what has been an increasing number of studies. On January 26, 2006, The New England Journal of Medicine (NEJM) published an article that linked Trasylol with potentially fatal side effects including kidney failure. Following mounting evidence of the drug’s serious side effects, Trasylol was finally voluntarily recalled from the marketplace by Bayer on November 5, 2007.

Each year approximately one million patients undergo surgery following a heart attack. Prior to Trasylol being withdrawn from the marketplace, the majority of patients who were at increased risk of bleeding during surgery had the option of one of three antifibrinolytic drugs to limit blood loss: Trasylol (Aprotinin), Amicar (aminocaproic acid), or Cyklokapron (tranexamic acid). These drugs work by inactivating an enzyme called plasmin so it stops from breaking down blood clots which helps prevent bleeding.

Trasylol affects the way in which blood clots. It is used during open heart surgery to help reduce excessive bleeding side effects. Trasylol is primarily administered during repeat coronary artery bypass surgery to prevent bleeding both during and after surgery. The drug has been in use for 13 years and millions of patients around the world have received it. One of the most serious complications for bypass surgery patients is excessive bleeding. Clotting medications such as Trasylol reduce the amount of blood transfusion needed during surgery. In 2006 The New England Journal of Medicine (NEJM) published a study that reported Trasylol problems with an increased risk of developing heart failure, kidney damage, myocardial infarction, and stroke in bypass heart surgery patients.

Patients and families around the United States are filing Trasylol lawsuits based on the side effects of the drug. Currently no Trasylol class action suits have been filed and claims are being filed individually. The lawsuits claim that the drug’s manufacturer, Bayer, was negligent in several different ways including strict liability, fraud, misrepresentation, deceptive trade practices and breach of express and implied warranties. Trasylol (Aprotinin) is a naturally occurring enzyme inhibitor obtained from bovine lung. The FDA approved Trasylol 1993 to help control bleeding in bypass heart surgery patients. Since its approval, Trasylol has been administered to around 4.3 million patients.

About the Author:
Steve Fields is a Minneapolis, Minnesota attorney representing clients in Trasylol lawsuits throughout the United States. The firm’s practice includes pharmaceutical litigation, product liability litigation, wrongful death, car and truck accidents, disability and workers compensation. Find more information about Trasylol Kidney Failure Attorneys here.